Age dependence of tumor genetics in unfavorable neuroblastoma: ArrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Cetinkaya, Cihan ^a,b   Martinsson, Tommy ^c   Sandgren, Johanna ^a,d   Träger, Catarina ^e   Kogner, Per ^e   Dumanski, Jan ^a   Díaz de Ståhl, Teresita ^a,d   Hedborg, Fredrik ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Age; Amplification; Arraycgh; DNA copy number; Gain; High risk; Loss; Neuroblastoma; Unfavorable

Indexed keywords

ADOLESCENT; AGE; AMPLICON; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CANCER GENETICS; CANCER REGISTRY; CANCER RISK; CHILD; CHROMOSOME 11Q; CHROMOSOME 12Q; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; INFANT; MALE; MYCN GENE; NEUROBLASTOMA; PRESCHOOL CHILD; SCHOOL CHILD; SWEDEN; TUMOR GENE; VALIDATION STUDY;

ADOLESCENT; AGE FACTORS; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 12; DNA COPY NUMBER VARIATIONS; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; INFANT; NEUROBLASTOMA; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS; REGISTRIES; SEQUENCE DELETION; SWEDEN;

EID: 84877112272     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-231     Document Type: Article

References (35)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003, 3(3):203-216. 10.1038/nrc1014, 12612655.
2. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010, 362(23):2202-2211. 10.1056/NEJMra0804577, 3306838, 20558371.
3. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010, 24(1):65-86. 10.1016/j.hoc.2009.11.011, 20113896.
4. Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 1997, 79(10):2028-2035. 10.1002/(SICI)1097-0142(19970515)79:10<2028::AID-CNCR26>3.0.CO;2-V, 9149032.
5. Polishchuk AL, Dubois SG, Haas-Kogan D, Hawkins R, Matthay KK. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer 2011, 117(18):4286-4293. 10.1002/cncr.25987, 3125487, 21387264.
6. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984, 224(4653):1121-1124. 10.1126/science.6719137, 6719137.
7. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009, 27(7):1026-1033. 10.1200/JCO.2008.16.0630, 19171713.
8. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005, 353(21):2243-2253. 10.1056/NEJMoa052399, 16306521.
9. Spitz R, Hero B, Simon T, Berthold F. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2006, 12(11 Pt 1):3368-3373.
10. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol 2009, 27(2):289-297. 10.1200/JCO.2008.16.6785, 2650388, 19047291.
11. Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm A, Molenaar JJ, Menten B, Marques B, Stallings RL. ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 2007, 46(12):1098-1108. 10.1002/gcc.20496, 17823929.
12. Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, Jagannathan J, Bhambhani K, Winter C, Maris JM. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 2007, 46(10):936-949. 10.1002/gcc.20477, 17647283.
13. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, Mosseri V, Valent A, Auger N, Plantaz D. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol 2010, 28(19):3122-3130. 10.1200/JCO.2009.26.7955, 20516441.
14. Hedborg F, Lindgren PG, Johansson I, Kogner P, Samuelsson BO, Bekassy AN, Olsen L, Kreuger A, Pahlman S. N-myc gene amplification in neuroblastoma: a clinical approach using ultrasound guided cutting needle biopsies collected at diagnosis. Med Pediatr Oncol 1992, 20(4):292-300. 10.1002/mpo.2950200405, 1608350.
15. Caren H, Kryh H, Nethander M, Sjoberg RM, Trager C, Nilsson S, Abrahamsson J, Kogner P, Martinsson T. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A 2010, 107(9):4323-4328. 10.1073/pnas.0910684107, 2840092, 20145112.
16. Diaz De Stahl T, Sandgren J, Piotrowski A, Nord H, Andersson R, Menzel U, Bogdan A, Thuresson AC, Poplawski A, Von Tell D. Profiling of copy number variations (CNVs) in healthy individuals from three ethnic groups using a human genome 32 K BAC-clone-based array. Hum Mutat 2008, 29(3):398-408. 10.1002/humu.20659, 18058796.
17. Sambrook JFE, Maniatis T. Molecular Cloning; a Laboratory Manual 1989, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
18. Ameur A, Yankovski V, Enroth S, Spjuth O, Komorowski J. The LCB data warehouse. Bioinformatics 2006, 22(8):1024-1026. 10.1093/bioinformatics/btl036, 16455749.
19. Andersson R, Bruder CE, Piotrowski A, Menzel U, Nord H, Sandgren J, Hvidsten TR, Diaz de Stahl T, Dumanski JP, Komorowski J. A segmental maximum a posteriori approach to genome-wide copy number profiling. Bioinformatics 2008, 24(6):751-758. 10.1093/bioinformatics/btn003, 18204059.
20. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002, 30(4):e15. 10.1093/nar/30.4.e15, 100354, 11842121.
21. Caren H, Erichsen J, Olsson L, Enerback C, Sjoberg RM, Abrahamsson J, Kogner P, Martinsson T. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics 2008, 9:353. 10.1186/1471-2164-9-353, 2527340, 18664255.
22. Lastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C, Roberts P, Hall AG, Tweddle DA, Pearson AD. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 2007, 26(53):7432-7444. 10.1038/sj.onc.1210552, 17533364.
23. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:Article3.
24. Benjamini YHY. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995, (Ser B 57):289-300.
25. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, Brinkschmidt C, Christiansen H, Combaret V, Lastowska M. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005, 23(10):2280-2299.
26. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012, 483(7391):589-593. 10.1038/nature10910, 22367537.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013, 21376230.
28. Fischer M, Bauer T, Oberthur A, Hero B, Theissen J, Ehrich M, Spitz R, Eils R, Westermann F, Brors B. Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene 2010, 29(6):865-875. 10.1038/onc.2009.390, 19901960.
29. Buckley PG, Alcock L, Bryan K, Bray I, Schulte JH, Schramm A, Eggert A, Mestdagh P, De Preter K, Vandesompele J. Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res 2010, 16(11):2971-2978. 10.1158/1078-0432.CCR-09-3215, 2880207, 20406844.
30. Chen QR, Bilke S, Wei JS, Whiteford CC, Cenacchi N, Krasnoselsky AL, Greer BT, Son CG, Westermann F, Berthold F. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. BMC Genomics 2004, 5:70. 10.1186/1471-2164-5-70, 520814, 15380028.
31. Carr J, Bown NP, Case MC, Hall AG, Lunec J, Tweddle DA. High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays. Cancer Genet Cytogenet 2007, 172(2):127-138. 10.1016/j.cancergencyto.2006.08.012, 17213021.
32. Corvi R, Savelyeva L, Amler L, Handgretinger R, Schwab M. Cytogenetic evolution of MYCN and MDM2 amplification in the neuroblastoma LS tumour and its cell line. Eur J Cancer 1995, 31A(4):520-523.
33. Rudolph G, Schilbach-Stuckle K, Handgretinger R, Kaiser P, Hameister H. Cytogenetic and molecular characterization of a newly established neuroblastoma cell line LS. Hum Genet 1991, 86(6):562-566.
34. Su WT, Alaminos M, Mora J, Cheung NK, La Quaglia MP, Gerald WL. Positional gene expression analysis identifies 12q overexpression and amplification in a subset of neuroblastomas. Cancer Genet Cytogenet 2004, 154(2):131-137. 10.1016/j.cancergencyto.2004.02.009, 15474148.
35. Amati B, Littlewood TD, Evan GI, Land H. The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J 1993, 12(13):5083-5087. 413769, 8262051.